All In MedTech

Device Trial Radar · NCT07101809

Trial of Ureteroscopy vs Steerable Continuous Flow Aspiration Technology

Evaluating the Safety and Effectiveness of Steerable Ureteroscopic Renal Evacuation (SURE) With the CVAC® System Compared to Standard Ureteroscopy With no Suction for the Treatment of Renal Stones: a Prospective, Randomized Trial

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

May 21, 2026

Primary completion

Jul 2027

Study completion Jul 2029

Sponsor

Lead sponsor
Calyxo, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 3, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC System and standard ureteroscopy (URS) with laser lithotripsy for the treatment of urolithiasis. This is a prospective, randomized (1:1), multi-center study.

Conditions

  • Urolithiasis
  • Stones, Kidney
  • Renal Stones
  • Kidney Stones

Interventions

  • Steerable Ureteroscopic Renal Evacuation (SURE) using the CVAC SystemDevice

    The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).

  • Standard Ureteroscopy (URS)Device

    Arm Description: This is a treatment in which the urologist uses a laser to break a kidney stone into very small pieces and then places a tool called a stent to allows the remaining pieces to fall out.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Residual Stone Volume (RSV)Time frame: 30-Day

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.